Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma

Claveau, Jean-Sébastien; Bélanger, Sophie Savary; Ahmad, Imran; Delisle, Jean-Sébastien; Guire, Vincent De; Roy, Jean; LeBlanc, Richard

doi:10.1038/s41408-021-00600-6

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, mostly all patients with negative Mass-Fix reached MRD negativity (85%). Some of the disparities observed between patients achieving MRD negativity with positive Mass-Fix could be related to longer halflife of immunoglobulins in comparison with bone marrow PCs [11]. Indeed, many patients included in this study had late mass spectrometry conversion (positive-> negative).…”

mentioning

confidence: 95%

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

et al. 2022

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 95%

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…Although sFLCs are a good real-time indicator of tumor burden, an unresolved question is whether part of this reduction could be related to cancer treatment, especially in patients with a possible underlying PID. Recent studies indicate an earlier reduction in sFLC after treatment compared with other biomarkers [ 47 ]. On the other hand, fluctuating levels of sFLC have been associated with temporary tumor inhibition and may be a marker of tumor resistance.…”

Section: Discussionmentioning

confidence: 99%

Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression

et al. 2022

View full text Add to dashboard Cite

B cell chronic lymphoproliferative diseases (B-CLPD) are associated with secondary antibody deficiency and other innate and adaptive immune defects, whose impact on infectious risk has not been systematically addressed. We performed an immunological analysis of a cohort of 83 B-CLPD patients with recurrent and/or severe infections to ascertain the clinical relevance of the immune deficiency expression. B-cell defects were present in all patients. Patients with combined immune defect had a 3.69-fold higher risk for severe infection (p = 0.001) than those with predominantly antibody defect. Interestingly, by Kaplan–Meier analysis, combined immune defect showed an earlier progression of cancer with a hazard ratio of 3.21, than predominantly antibody defect (p = 0.005). When B-CLPD were classified in low-degree, high-degree, and plasma cell dyscrasias, risk of severe disease and cancer progression significantly diverged in combined immune defect, compared with predominantly antibody defect (p = 0.001). Remarkably, an underlying primary immunodeficiency (PID) was suspected in 12 patients (14%), due to prior history of infections, autoimmune and granulomatous conditions, atypical or variegated course and compatible biological data. This first proposed SID classification might have relevant clinical implications, in terms of predicting severe infections and cancer progression, and might be applied to different B-CLPD entities.

show abstract

Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma

Teo,

Ong,

Tong

et al. 2023

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma

Cited by 5 publications

References 15 publications

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression

Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma

Contact Info

Product

Resources

About